New York Fertility Mandate Billing: Unlimited IVF Coverage Rules

New York's fertility insurance mandate is among the strongest in the country, distinguished from peer state mandates by a single critical feature: there is no statutory lifetime cap on the number of covered IVF cycles. Unlike Illinois, which limits coverage to four lifetime IVF retrievals, and many other mandate states that impose two- or three-cycle ceilings, New York law requires qualifying fully insured large-group plans to cover medically necessary infertility treatment without a numerical limit on retrievals. For fertility practices serving a commercially insured New York patient population, this unlimited cycle structure creates both an opportunity to capture ongoing revenue from multi-cycle patients and a corresponding compliance obligation to manage authorizations, cycle tracking, and documentation accurately across extended treatment courses.

This post covers the statutory foundation of the New York mandate, the scope of covered services, applicable CPT and ICD-10 codes, carrier-specific prior authorization requirements for the major New York commercial carriers, FET billing rules, same-sex couple and single patient protocols, and the highest-impact billing errors that generate claim denials under NY mandate plans.

The Statutory Foundation: New York Insurance Law §3221(k)(6)

New York's fertility mandate is codified in New York Insurance Law §3221(k)(6) for group accident and health insurance policies and in corresponding provisions of the Public Health Law for HMO and managed care plans. The mandate was enacted by Chapter 59 of the Laws of 2019, signed April 12, 2019, and became effective for plans issued or renewed on or after April 1, 2020. The New York Department of Financial Services (DFS) issued implementing guidance and model language to assist carriers in revising plan documents for compliance. The statute requires group accident and health insurance policies that provide coverage for hospital or medical expenses to include coverage for the diagnosis and treatment of infertility, including in vitro fertilization, for covered employees and dependents who meet the statutory criteria. The statute does not impose a per-lifetime retrieval cycle limit — which is the defining legislative choice that distinguishes New York's mandate from Illinois (4 retrievals), New Jersey, and most other mandate states.

The mandate applies to group policies delivered or issued for delivery in New York covering 100 or more employees. Individual policies and small-group plans (fewer than 100 employees) are not subject to the same unlimited IVF mandate requirement, though some carriers include fertility benefits in small-group products voluntarily or pursuant to other plan terms. As with all state insurance mandates, the federal ERISA preemption provision exempts self-funded employer health plans from state mandate compliance. A plan's ERISA-governed status is determined by the source of funding — employer contributions bearing the financial risk versus premium payments to a licensed insurer — not by which insurance company's name appears on the member ID card. Confirming plan funding type at every initial eligibility verification is not optional for New York fertility practices; it is the foundational step on which all subsequent coverage determinations depend.

Plan Eligibility: Which New York Plans Are Subject to the Mandate

A New York plan is subject to the unlimited IVF mandate if it meets all three of the following: (1) it is a group accident and health insurance policy or managed care contract issued, delivered, or renewed in New York State; (2) it covers 100 or more employees; and (3) it is fully insured — meaning the licensed insurer bears the financial risk, not the employer. When all three conditions are met, the plan must provide coverage for infertility diagnosis and treatment, including IVF, without a lifetime cycle cap. When any one condition is absent, the mandate does not apply: a self-funded plan covering 10,000 New York employees has no mandate obligation; a 200-employee group plan issued in New Jersey that covers a New York-based employee is subject to New Jersey's mandate, not New York's; and an individual or family plan is subject to different NY individual market fertility coverage rules.

In New York City and the surrounding metropolitan area, the mix of self-funded and fully insured large-group plans skews heavily toward self-funded for employers with 500 or more employees. Major financial institutions, law firms, hospital systems, and technology companies commonly self-fund their health benefits even when those plans are administered by Empire BlueCross, Aetna, or UHC. The presence of a New York address and a recognizable carrier on the insurance card is not sufficient to assume mandate coverage. Staff must ask the carrier's eligibility line directly — "Is this plan fully insured or self-funded?" — document the answer with the representative's name and the date, and not proceed with cycle services until the plan funding type is confirmed in the billing record.

Covered Fertility Services Under the New York Mandate

New York's mandate requires coverage for the diagnosis and treatment of infertility. Covered services include the full spectrum of clinically recognized infertility evaluation and treatment:

• Infertility diagnostic workup: comprehensive baseline labs (FSH 83001; LH 83002; estradiol 82670; AMH; prolactin 84146; TSH 84443), semen analysis (89300 — sperm count and concentration; 89310 — motility and count; 89320 — complete analysis; 89322 — complete with strict Kruger morphology), hysterosalpingography (74740 for fluoroscopic or 58340 for sonographic/office-based), antral follicle count by transvaginal ultrasound (76830), diagnostic hysteroscopy (58555), diagnostic laparoscopy (49320 or 58660), and endometrial biopsy (58100)
• IVF — complete fresh cycle including controlled ovarian stimulation, follicle ultrasound monitoring (76817 transvaginal; 76830 transabdominal), serial estradiol and LH monitoring labs, oocyte retrieval (58970) with ultrasound guidance (76948), conventional oocyte insemination (89268), ICSI (89280 for ≤10 oocytes; 89281 for >10 oocytes), embryo culture (89250), extended embryo culture to blastocyst (89272), and embryo transfer (58974)
• Frozen embryo transfer (FET): embryo cryopreservation (89258), embryo thaw and preparation (89352), and FET embryo transfer procedure (58974); FET cycles are covered under most NY mandate plans and require standalone prior authorization separate from the IVF retrieval authorization
• IUI (intrauterine insemination): sperm wash and preparation (89260) and the insemination procedure (58322); the mandate covers IUI, though plan-level IUI cycle limits may apply within the mandate framework
• Preimplantation genetic testing (PGT): embryo biopsy for PGT (89290 for ≤5 embryos; 89291 for >5 embryos); PGT-A is covered when medically indicated under most NY mandate plans with separate prior authorization; PGT-M and PGT-SR have additional documentation requirements and carrier-specific clinical criteria
• Iatrogenic fertility preservation: oocyte cryopreservation (89337) prior to gonadotoxic treatment (chemotherapy, pelvic radiation, or surgical intervention threatening ovarian function) is covered using the oncology primary diagnosis code and Z31.62 — never use N97.x infertility diagnosis codes for iatrogenic preservation patients, as this triggers a medical necessity review under infertility criteria that the patient will fail
• Ovarian reserve testing as a covered diagnostic service: AMH testing, antral follicle count by transvaginal ultrasound (76830), and Day 3 FSH, LH, and estradiol panels

Services not required to be covered under the NY mandate include: elective (social) egg freezing performed in the absence of a medical indication that threatens future fertility; third-party donor egg acquisition fees or compensation paid directly to an egg donor; third-party sperm donor purchase fees (though the insemination procedure itself is covered); gestational carrier or surrogacy fees paid to the carrier; annual embryo, oocyte, or sperm cryostorage fees (storage is typically a patient out-of-pocket expense unless separately covered by a plan rider); and any procedure classified as investigational or experimental under the carrier's current fertility medical policy.

CPT Code Reference for New York Mandate Fertility Services

ICD-10 Diagnosis Coding for New York Mandate Claims

New York mandate claims require ICD-10 codes that accurately reflect the patient's infertility diagnosis and etiology. Carriers use the primary diagnosis code to route the claim to the fertility benefit and validate medical necessity. Using an unspecified code when a specific etiology is documented increases the risk of supplemental documentation requests and delays reimbursement. For IVF cycle claims, the primary diagnosis should be the most specific female infertility code consistent with the documented clinical findings; secondary codes should include applicable etiologic, procedural, and encounter codes.

Primary infertility diagnosis codes: N97.0 (female infertility associated with anovulation — use for PCOS, hypothalamic dysfunction, anovulatory cycles; add E28.2 as secondary when PCOS is the specific etiology); N97.1 (female infertility of tubal origin — documented tubal occlusion, prior ectopic pregnancy, prior salpingectomy, tubal ligation reversal); N97.2 (female infertility of uterine origin — uterine anomaly, Asherman's syndrome, submucosal fibroid as primary cause); N97.8 (female infertility of other or combined origin — when two distinct etiologies are present, or etiology does not fit a more specific category); N97.9 (female infertility, unspecified — use only when no etiology can be documented; the weakest code for medical necessity defense, and carriers may require supplemental documentation when this code appears as the primary). Male factor supporting codes: N46.01 (organic azoospermia), N46.11 (organic oligospermia), N46.021–N46.029 (azoospermia by etiology), N46.121–N46.129 (oligospermia by etiology). Secondary encounter codes for all IVF and FET claims: Z31.83 (encounter for assisted reproductive fertility procedure) — include as a secondary code on every IVF and FET claim; Z31.41 (encounter for fertility testing) — for diagnostic workup claims; Z31.62 (encounter for fertility preservation procedure) — for iatrogenic cases only. For iatrogenic fertility preservation, the primary diagnosis is the oncology code (e.g., C50.x for breast cancer; C56.x for ovarian cancer); N97.x infertility codes must never appear on these claims. For same-sex couple and single patient IVF cycles where no infertility diagnosis exists (the patient is reproductively competent but requires donor sperm), use Z31.89 (encounter for other procreative management) as primary with Z31.83 as secondary.

Prior Authorization Requirements by Major New York Carrier

Every major New York commercial carrier requires prior authorization for IVF, FET, PGT, and in most cases, monitored IUI cycles. The authorization submission pathway differs by carrier; routing a PA to the wrong entity or portal results in no valid authorization being issued, producing a claim denial at adjudication even for services that are mandate-compliant and clinically appropriate.

• Empire BlueCross BlueShield (Anthem NY) — Empire is the dominant fully insured commercial carrier in New York by enrollment. For most Empire fully insured large-group products, fertility prior authorization is delegated to AIM Specialty Health (aimspecialtyhealth.com). IVF, FET, and PGT authorizations must be submitted through the AIM portal — submitting directly to Empire produces no authorization in AIM's system, and the claim denies for lack of PA at adjudication. Confirm the authorization pathway at every initial eligibility verification; some Empire products (state employee plans, certain managed care products) retain PA in-house. AIM standard review is 3–5 business days; expedited review (24–48 hours) is available for time-sensitive clinical situations. FET and PGT each require standalone PA separate from the IVF retrieval authorization. AIM's clinical criteria for NY mandate plans require documentation of the infertility diagnosis and etiology, duration and etiology of infertility, prior treatment history, and the treating physician's treatment plan. PA is typically valid for 90 days.
• UnitedHealthcare (UHC) New York — UHC's NY fully insured large-group plans require fertility PA through UHC's national fertility authorization process. For some UHC products, fertility PA routes through Optum; confirm the correct submission pathway at eligibility verification. Submitting through the wrong portal results in a parallel authorization problem at adjudication. UHC's clinical criteria include documented infertility meeting the NY statutory definition, prior treatment history consistent with the requested service, and the physician's clinical rationale for the proposed cycle. FET, PGT, and IUI each require separate authorization from the IVF retrieval PA. Standard PA turnaround is 3–5 business days; PA is typically valid for 90–180 days.
• Aetna New York — Aetna's NY fully insured group plans handle fertility PA in-house through Aetna's national fertility PA team. Submit through the Aetna provider portal or by calling the specialty PA line. Aetna's clinical criteria require documentation of the infertility diagnosis and etiology, duration of infertility, prior treatment history, and the physician's treatment plan. Aetna may request IUI cycle documentation as part of an IVF authorization package — if IUI was attempted and failed, include those records; if IUI was clinically contraindicated, include the treating physician's written contraindication statement explicitly noting the clinical basis. FET and PGT each require standalone PA. Aetna's NY mandate PA is typically valid for 90 days.
• Cigna New York — Cigna handles fertility PA through its national specialty PA process for NY fully insured group plans. Cigna's IVF clinical criteria may include a 3-cycle IUI requirement before IVF approval, even for NY mandate patients. If IUI is clinically contraindicated (severe male factor, bilateral tubal occlusion, prior repeated IUI failures), document the contraindication explicitly in the PA package and reference the NY mandate's requirement to cover medically necessary IVF without imposing barriers that are inconsistent with the statute — applying a categorical IUI prerequisite to a patient with a documented contraindication is a valid basis for appeal. Cigna PA is typically valid for 90 days. FET and PGT require separate PA.
• MVP Health Care (upstate NY) — MVP is a regional carrier with significant fully insured group enrollment in upstate New York and the Capital Region. MVP fertility PA is submitted through the MVP provider portal or by phone to MVP's utilization management team. MVP's fertility coverage rules for NY mandate-compliant fully insured large-group products follow the NY Insurance Law §3221(k)(6) requirements. Confirm coverage and authorization requirements with MVP provider relations annually, as regional carrier policies evolve and may differ materially from national carrier protocols.
• Fidelis Care / WellCare New York — Fidelis operates primarily in the Medicaid managed care and commercial individual/small-group market. Large-group fully insured Fidelis plans subject to the mandate follow Fidelis's commercial fertility PA process. Many Fidelis products are Medicaid managed care and governed by NY Medicaid fertility coverage rules rather than the commercial mandate — confirm plan type and mandate applicability at eligibility before assuming unlimited IVF coverage.

FET Billing Under New York Mandate Plans

FET billing is a recurring source of claim denials in New York practices. Billing staff who correctly understand that the IVF mandate is "unlimited" sometimes apply the IVF retrieval authorization to FET claims as a shortcut. This produces an immediate clinical inconsistency denial: the FET CPT codes (89352 for embryo thaw; 58974 for FET embryo transfer) are not within the authorized scope of an oocyte retrieval authorization (58970). Every FET cycle requires its own standalone prior authorization, submitted and approved before the FET monitoring cycle begins. The FET authorization must reference the current mandate benefit, include documentation of the embryo inventory and cycle plan, and be confirmed as active before any FET monitoring claims are submitted.

Whether FET cycles are subject to any separate cycle limit under a NY mandate plan must be confirmed with each carrier at initial eligibility verification. Under most New York fully insured large-group plans, FET cycles are covered without a numeric cap consistent with the unlimited IVF retrieval benefit — but individual plan documents vary, and some plans impose standalone FET cycle limits. Collect the FET benefit details (cycle limit if any, authorization requirement, and clinical criteria) separately from the IVF retrieval benefit at initial eligibility verification. Do not assume FET benefit rules mirror retrieval benefit rules. For patients transferring frozen embryos from another clinic, obtain written records of prior FET cycles at the previous facility and confirm with the current insurer whether those cycles have been applied to any benefit limit.

Same-Sex Couples and Single Patients Under the NY Mandate

New York's mandate extends to same-sex couples and single individuals. Rather than requiring documented unprotected heterosexual intercourse for the statutory 6- or 12-month period, NY carriers must apply a clinically appropriate alternative pathway for patients who cannot conceive through unprotected intercourse — typically a physician-supervised therapeutic donor insemination (TDI) protocol. The number of TDI cycles required before an IVF authorization is approved varies by carrier's clinical criteria; some NY carriers require 3–6 supervised TDI cycles, while others allow the treating REI to justify proceeding directly to IVF based on clinical factors such as advanced maternal age, severely diminished ovarian reserve, or a medical contraindication to IUI. PA documentation requirements for same-sex and single patient authorizations include:

• Records of all prior physician-supervised TDI or monitored insemination cycles, including dates, protocol, outcomes, and supervising provider — collect from all prior treating clinics, not only your own facility
• The treating REI physician's written statement documenting the TDI protocol and outcomes, or an explicit clinical justification for proceeding directly to IVF without TDI cycles (e.g., documented AMH below 1.0 ng/mL, AFC ≤5–6, age ≥40, prior IUI failures, bilateral tubal occlusion)
• Confirmation that the insemination cycles used donor sperm or partner gametes as appropriate and were physician-supervised — self-insemination cycles do not qualify under most carrier clinical criteria and may prompt a request for documentation of supervising provider records
• For same-sex female couples where one partner carries and one partner provides oocytes (reciprocal IVF or RIVF): confirm with the carrier which partner is the billing patient for the retrieval cycle and which is the billing patient for the transfer cycle; bill the retrieval under the egg-providing partner's benefits and the transfer under the recipient partner's benefits
• ICD-10 coding for same-sex and single patient IVF with no infertility diagnosis: use Z31.89 (encounter for other procreative management) as primary with Z31.83 (encounter for assisted reproductive fertility procedure) as secondary; when a co-existing infertility diagnosis is present (e.g., diminished ovarian reserve in a same-sex female patient), use the specific N97.x code as primary and Z31.83 as secondary

Common New York Mandate Billing Errors and Prevention

• Assuming mandate coverage for self-funded plans: The most costly billing error in New York fertility practices. ERISA self-funded plans are not subject to the NY mandate. A recognizable carrier name on the member ID card does not indicate fully insured status. Prevention: confirm fully insured status at every initial eligibility call; document the response, representative name, and date; flag self-funded patients separately in your billing system before any cycle services are authorized or rendered.
• Applying the IVF retrieval authorization to FET claims: FET CPT codes (89352 and 58974) are outside the scope of an oocyte retrieval authorization. Claims billed under the retrieval auth number are denied for clinical inconsistency. Prevention: build a mandatory FET authorization workflow trigger that activates when a freeze-all cycle completes, when PGT results are received, or when a fresh transfer is cancelled due to OHSS risk or embryo quality concerns.
• Routing Empire BCBS NY fertility PA directly to Empire instead of through AIM Specialty Health: For most Empire fully insured large-group products, fertility PA must be submitted through AIM Specialty Health — not Empire's standard PA portal or phone line. Submitting to Empire produces no record in AIM's system and the claim denies for lack of PA. Prevention: verify the PA vendor at eligibility verification; document AIM as the fertility PA pathway for Empire large-group plans; audit carrier-to-vendor routing annually.
• Submitting PGT biopsy codes (89290, 89291) under the IVF retrieval authorization: PGT requires standalone prior authorization for most NY carriers. Billing 89290 or 89291 under the retrieval auth produces a denial. Prevention: make PGT authorization a required pre-cycle workflow step whenever PGT is planned; confirm the PGT auth number is on file before submitting biopsy claims.
• Using infertility ICD-10 codes for iatrogenic fertility preservation patients: Applying N97.x to an oncology patient's pre-chemotherapy egg freeze triggers a medical necessity review under infertility criteria that the patient cannot satisfy. The claim denies. Prevention: build a clinical trigger in your intake workflow that identifies patients undergoing gonadotoxic treatment and routes their claims to the iatrogenic preservation coding protocol (oncology primary diagnosis + Z31.62).
• Submitting a new IVF retrieval PA when the patient has a viable cryopreserved embryo inventory: NY carriers may deny a new retrieval PA when the patient has frozen embryos available, on the grounds that a clinically equivalent and less invasive alternative (FET) exists. Prevention: review embryo inventory before submitting a retrieval PA for any patient with frozen embryos; include the physician's clinical rationale for new retrieval in the PA package (e.g., poor embryo quality, insufficient embryo number, prior failed FETs from the existing inventory, change in clinical protocol).
• Missing or incomplete TDI documentation for same-sex and single patient authorization packages: PA packages submitted without complete supervised TDI records are returned for supplemental documentation, delaying the authorization. Prevention: create a same-sex and single patient intake checklist with prior TDI documentation collection as a required step; assign responsibility to a specific staff member with a defined collection deadline before the PA submission date.
• Not requesting expedited PA review when a cycle is time-sensitive: Standard PA turnaround (3–5 business days) may cause a patient to miss her optimal stimulation window if submitted late. Prevention: request expedited review for any PA submitted within 5 business days of the anticipated cycle start date; document the clinical basis for expedited review (age, cycle day, ovarian reserve metrics) in the submission.

Appealing New York Mandate Coverage Denials

New York fully insured plans are subject to robust external appeal rights under New York Insurance Law and the ACA. After exhausting the plan's internal appeal process — typically 60 days from the date of the adverse determination — patients and providers may request an external independent review through the New York State Department of Financial Services (DFS) or, for HMO plans, through a DFS-approved independent review organization (IRO). External review decisions in New York are binding on fully insured insurers. Self-funded ERISA plans are not subject to the New York DFS process; ERISA plans have limited federal external review rights under the ACA's external review regulations.

For NY mandate medical necessity denials, the internal appeal package should include: the complete infertility workup documentation establishing diagnosis and etiology; confirmation that the patient meets the New York statutory infertility definition (including TDI cycle records for same-sex and single patients); prior treatment history relevant to the proposed service; the treating REI physician's signed letter of medical necessity; applicable ASRM Practice Committee Opinion guidelines supporting the requested service for the patient's specific diagnosis; peer-reviewed literature; and a written argument identifying where the carrier's denial conflicts with New York Insurance Law §3221(k)(6) and the DFS implementing guidance. For denials applying an IUI cycle prerequisite to a patient with a documented IUI contraindication, include the physician's written contraindication statement and cite the NY mandate's obligation to cover medically necessary IVF without barriers inconsistent with the statute. Request a concurrent peer-to-peer review with the carrier's medical director within 48 hours of a time-sensitive denial. For Empire BCBS NY plans with PA delegated to AIM Specialty Health, the peer-to-peer is with an AIM physician reviewer and is typically scheduled within two business days; document the verbal outcome immediately after the call and follow up in writing if a revised authorization is not issued within 24 hours.

Quarterly Billing Audit Checklist for New York Practices

A quarterly audit of New York mandate billing should confirm: every IVF, FET, PGT, and monitored IUI claim has a matching authorization number on file before submission; Empire BCBS NY fertility PA is routed through AIM Specialty Health and not submitted directly to Empire; plan funding type is documented at the patient level and confirmed as fully insured before any cycle services are authorized; FET authorizations are standalone and not linked to the IVF retrieval authorization number; same-sex and single patient files contain complete supervised TDI documentation collected before the PA submission date; PGT biopsy claims reference a PGT-specific authorization separate from the IVF retrieval authorization; iatrogenic preservation claims use oncology primary diagnoses and Z31.62 — not N97.x codes; new retrieval PAs for patients with a frozen embryo inventory include a physician-authored rationale for retrieval over FET; all denial-to-internal-appeal turnaround times are within the plan-specific internal appeal deadline; and external review eligibility is tracked for all internally upheld denials to ensure patients do not forfeit DFS appeal rights by missing the submission deadline.